Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [395]

Outcomes in paediatric oncology: Are we closing the gap between LMICs and high...

Prof Laila Hessissen - Mohammed V University of Rabat, Rabat, Morocco

Outcomes in paediatric oncology: Are we closing the gap between LMICs and high-income countries? ( Prof Laila Hessissen - Mohammed V University of Rabat, Rabat, Morocco )

CAR-T cell therapy for ALL: Current challenges and future approaches

Dr Sara Ghorashian - University College London, London, UK

CAR-T cell therapy for ALL: Current challenges and future approaches ( Dr Sara Ghorashian - University College London, London, UK )

CART-T cell therapy in young patients with relapsed/refractory ALL

Prof Peter Bader - Universitätsklinikum Frankfurt, Frankfurt, Germany

$CART-T cell therapy in young patients with relapsed/refractory ALL ( Prof Peter Bader - Universitätsklinikum Frankfurt, Frankfurt, Germany )$

The role of blinatumomab followed by HSCT in paediatric patients with ALL

Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy

The role of blinatumomab followed by HSCT in paediatric patients with ALL ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )

Long-term toxicities in paediatric ALL

Prof Kjeld Schmiegelow - University of Copenhagen, Copenhagen, Denmark

Long-term toxicities in paediatric ALL ( Prof Kjeld Schmiegelow - University of Copenhagen, Copenhagen, Denmark )

Frontline therapy of ALL

Prof Hervé Dombret - University Paris Diderot, Paris, France

Frontline therapy of ALL ( Prof Hervé Dombret - University Paris Diderot, Paris, France )

BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL

Prof Hervé Dombret - University Paris Diderot, Paris, France

BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL ( Prof Hervé Dombret - University Paris Diderot, Paris, France )

Identifying cancer susceptibility genes in paediatric ALL

Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA

Identifying cancer susceptibility genes in paediatric ALL ( Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA )

Latest concepts in frontline therapy for paediatric ALL

Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA

Latest concepts in frontline therapy for paediatric ALL ( Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA )

Dasatinib vs imatinib in the treatment of paediatric ALL

Dr Shuhong Shen - National Children's Medical Center, Shanghai, China

Dasatinib vs imatinib in the treatment of paediatric ALL ( Dr Shuhong Shen - National Children's Medical Center, Shanghai, China )

FLT3-inhibition in infants with acute lymphoblastic leukaemia

Dr Patrick Brown - Johns Hopkins University, Baltimore, USA

FLT3-inhibition in infants with acute lymphoblastic leukaemia ( Dr Patrick Brown - Johns Hopkins University, Baltimore, USA )

Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse...

Dr Patrick Brown - Johns Hopkins University, Baltimore, USA

Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse of B-ALL in children and adolescents ( Dr Patrick Brown - Johns Hopkins University, Baltimore, USA )

More from ecancer